These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 10348784)

  • 1. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration.
    Wise R; Andrews JM; Marshall G; Hartman G
    Antimicrob Agents Chemother; 1999 Jun; 43(6):1508-10. PubMed ID: 10348784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man.
    Stass H; Kubitza D
    J Antimicrob Chemother; 1999 May; 43 Suppl B():83-90. PubMed ID: 10382880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose.
    Wise R; Andrews JM; Ashby JP; Marshall J
    J Antimicrob Chemother; 1999 Nov; 44(5):701-4. PubMed ID: 10552990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Penetration of moxifloxacin into peripheral compartments in humans.
    Müller M; Stass H; Brunner M; Möller JG; Lackner E; Eichler HG
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2345-9. PubMed ID: 10508004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-dose pharmacokinetics and penetration of BMS 284756 into an inflammatory exudate.
    Wise R; Gee T; Marshall G; Andrews JM
    Antimicrob Agents Chemother; 2002 Jan; 46(1):242-4. PubMed ID: 11751144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.
    Stass H; Böttcher MF; Ochmann K
    Clin Pharmacokinet; 2001; 40 Suppl 1():39-48. PubMed ID: 11352441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trans-epithelial intestinal elimination of moxifloxacin in rabbits.
    Musafija A; Ramon J; Shtelman Y; Yoseph G; Rubinovitz B; Segev S; Rubinstein E
    J Antimicrob Chemother; 2000 Jun; 45(6):803-5. PubMed ID: 10837433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moxifloxacin penetration in bronchial secretions of mechanically ventilated patients with pneumonia.
    Leone M; Albanèse J; Sampol-Manos E; Simon N; Lacarelle B; Bruguerolle B; Martin C
    Antimicrob Agents Chemother; 2004 Feb; 48(2):638-40. PubMed ID: 14742226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration.
    Stass H; Kubitza D; Schühly U
    Clin Pharmacokinet; 2001; 40 Suppl 1():1-9. PubMed ID: 11352436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess.
    Rink AD; Stass H; Delesen H; Kubitza D; Vestweber KH
    Clin Drug Investig; 2008; 28(2):71-9. PubMed ID: 18211115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of age and gender on the pharmacokinetics of moxifloxacin.
    Sullivan JT; Lettieri JT; Liu P; Heller AH
    Clin Pharmacokinet; 2001; 40 Suppl 1():11-8. PubMed ID: 11352437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone.
    Sullivan JT; Woodruff M; Lettieri J; Agarwal V; Krol GJ; Leese PT; Watson S; Heller AH
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2793-7. PubMed ID: 10543767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of probenecid on the kinetics of a single oral 400mg dose of moxifloxacin in healthy male volunteers.
    Stass H; Sachse R
    Clin Pharmacokinet; 2001; 40 Suppl 1():71-6. PubMed ID: 11352445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absolute bioavailability of moxifloxacin.
    Ballow C; Lettieri J; Agarwal V; Liu P; Stass H; Sullivan JT
    Clin Ther; 1999 Mar; 21(3):513-22. PubMed ID: 10321420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers.
    Stass H; Schühly U; Möller JG; Delesen H
    Clin Pharmacokinet; 2001; 40 Suppl 1():49-55. PubMed ID: 11352442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans.
    Stass H; Kubitza D
    Clin Pharmacokinet; 2001; 40 Suppl 1():57-62. PubMed ID: 11352443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces.
    Burkhardt O; Borner K; Stass H; Beyer G; Allewelt M; Nord CE; Lode H
    Scand J Infect Dis; 2002; 34(12):898-903. PubMed ID: 12587622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and inflammatory fluid penetration of clinafloxacin.
    Wise R; Jones S; Das I; Andrews JM
    Antimicrob Agents Chemother; 1998 Feb; 42(2):428-30. PubMed ID: 9527799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects.
    Stass H; Dalhoff A; Kubitza D; Schühly U
    Antimicrob Agents Chemother; 1998 Aug; 42(8):2060-5. PubMed ID: 9687407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species.
    Siefert HM; Domdey-Bette A; Henninger K; Hucke F; Kohlsdorfer C; Stass HH
    J Antimicrob Chemother; 1999 May; 43 Suppl B():69-76. PubMed ID: 10382878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.